Jazz Pharmaceuticals: estimates $755,000,000 IPR&D charge from Actio deal

What happened

• Jazz Pharmaceuticals filed an 8-K on Oct 26, 2026 reporting that, in connection with its acquisition of Actio Biosciences, Inc. (completed Sep 15, 2026), it currently estimates a pre-tax acquired in-process research and development ("IPR&D") expense of approximately $755,000,000 for the third quarter of 2026.
• The filing states the expected IPR&D charge is not tax deductible and is estimated to represent an unfavorable impact of approximately $11.00 to both GAAP earnings per share and non-GAAP adjusted earnings per share for the third quarter of 2026. The company said quarter-end results have not been finalized and are subject to closing procedures.

Key details

• Acquisition of Actio Biosciences, Inc. completed Sep 15, 2026.
• Estimated pre-tax acquired IPR&D expense: approximately $755,000,000.
• Estimated impact to GAAP EPS and non-GAAP adjusted EPS for Q3 2026: approximately $11.00 per share (unfavorable).
• The filing discusses the company's non-GAAP adjusted EPS definition and notes that non-GAAP measures exclude items such as intangible asset amortization and share-based compensation and have no standardized meaning under GAAP.

Why it may matter

• The filing is Item 2.02 (results of operations and financial condition) and reports the company's preliminary estimate of a one-time acquired IPR&D charge tied to the Actio acquisition, plus related effects on GAAP and non-GAAP EPS for the quarter ended Sep 30, 2026. The filing also includes forward-looking statements and notes that actual results may differ from the estimates.
• This filing does not show why the company acted.